Article Information
History
- October 6, 2021.
Article Versions
- Version 1 (September 21, 2021 - 18:12).
- You are viewing Version 2, the most recent version of this article.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC 4.0 International license.
Author Information
- Nick Andrews1,2,
- Elise Tessier1,
- Julia Stowe1,
- Charlotte Gower1,
- Freja Kirsebom1,
- Ruth Simmons1,
- Eileen Gallagher1,
- Meera Chand1,3,
- Kevin Brown1,
- Shamez N Ladhani1,4,
- Mary Ramsay1,2 and
- Jamie Lopez Bernal1,2,5,*
- 1Public Health England, London, UK
- 2NIHR Health Protection Research Unit in Vaccines and Immunisation, London School of Hygiene and Tropical Medicine, London, UK
- 3Guys and St Thomas’s Hospital NHS Trust, London, UK
- 4Paediatric Infectious Diseases Research Group, St. George’s University of London, UK
- 5NIHR Health Protection Research Unit in Respiratory Infections, Imperial College London, London, UK
- ↵*Corresponding author; email: jamie.lopezbernal2{at}phe.gov.uk
Posted October 06, 2021.
Vaccine effectiveness and duration of protection of Comirnaty, Vaxzevria and Spikevax against mild and severe COVID-19 in the UK
